Patient Surveillance After Cancer Treatment

Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer.

The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients.

This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today’s practicing oncologist.

1. Overview

David Y. Johnson and Frank E. Johnson

2. Introduction to Cancer Surveillance Strategies

Brooke Crawford and David D. Greenberg

3. Using Decision Analysis to Model Cancer Surveillance

Kim E.M. van Kessel, Sandra M.E. Geurts, André L.M. Verbeek, and Ewout W. Steyerberg

4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment

Craig C. Earle and Jennifer Deevy

5. Upper Aerodigestive Tract Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe

Béatrix Barry and Dominique De Raucourt

7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan

Torahiko Nakashima, Ryuji Yasumatsu, and Shizuo Komune

8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada

Richard W. Nason and James B. Butler

9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia

Leigh Delbridge

11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan

Ryuji Yasumatsu, Torahiko Nakashima, and Shizuo Komune

12. Lung Carcinoma

Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

13. Lung Carcinoma Surveillance Counterpoint: Australia

Michael Boyer and Kate Mahon

14. Lung Carcinoma Surveillance Counterpoint: Japan

Tokujiro Yano and Yoshihiko Maehara

15. Lung Carcinoma Surveillance Counterpoint: Canada

Gail Darling, Yee Ung, Peter Ellis, Lorraine Martelli-Reid, and Bill Evans

16. Esophagus Carcinoma

Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

17. Esophagus Carcinoma Surveillance Counterpoint: Australia

Bernard Mark Smithers, Janine M. Thomas, and Bryan H. Burmeister

18. Esophagus Carcinoma Surveillance Counterpoint: Japan

Masaru Morita and Yoshihiko Maehara

19. Stomach

Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

20. Stomach Carcinoma Surveillance Counterpoint: USA

Andrew Coleman and Douglas Tyler

21. Stomach Carcinoma Surveillance Counterpoint: Japan

Yoshihiro Kakeji, Masaru Morita, and Yoshihiko Maehara

22. Pancreatic Adenocarcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA

Tanios S. Bekaii-Saab

24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe

Richard A. Smith, Jane V. Butler, and John P. Neoptolemos

25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan

Ken Shirabe and Yoshihiko Maehara

26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada

Malcolm J. Moore and Anastasios Stathis

27. Liver and Biliary Tract Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe

Michele Colledan

29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia

Michael D. Crawford

30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan

Akinobu Taketomi and Yoshihiko Maehara

31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada

Oliver F. Bathe and Kelly Warren Burak

32. Colon and Rectum Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA

Mohamedtaki A. Tejani and Steven J. Cohen

34. Colon and Rectum Carcinoma Surveillance Counterpoint: Australia

Toufic El-Khoury, Michael Solomon, and Jane Young

35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan

Yasushi Toh and Yoshihisa Sakaguchi

36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada

Marko Simunovic

37. Anal Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

38. Anal Carcinoma Surveillance Counterpoint: USA

Jonathan M. Hernandez, Erin M. Siegel, Abby Koch, and David Shibata

39. Anal Carcinoma Surveillance Counterpoint: Australia

Toufic El-Khoury, Michael Solomon, and Jane Young

40. Anal Carcinoma Surveillance Counterpoint: Japan

Yoshihisa Sakaguchi and Yasushi Toh

41. Anal Carcinoma Surveillance Counterpoint: Canada

Natasha Press and John Hay

42. Soft Tissue Sarcoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

43. Soft Tissue Sarcoma Surveillance Counterpoint: USA

Valeriy Sedov and Janice M. Mehnert

44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan

Shuichi Matsuda and Yukihide Iwamoto

45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada

Lloyd A. Mack and Vivien H.C. Bramwell

46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan

Shuichi Matsuda and Yukihide Iwamoto

48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada

Timothy R. Asmis, Joel Werier, and Shailendra Verma

49. Cutaneous Melanoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

50. Cutaneous Melanoma Surveillance Counterpoint: USA

Gerald Linette and Lynn A. Cornelius

51. Cutaneous Melanoma Surveillance Counterpoint: Australia

Michael A. Henderson

52. Cutaneous Melanoma Surveillance Counterpoint: Japan

Yoichi Moroi

53. Breast Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

54. Breast Carcinoma Surveillance Counterpoint: USA

Kelli Pettit and Julie A. Margenthaler

55. Breast Carcinoma Surveillance Counterpoint: Europe

Stefano Ciatto

56. Breast Carcinoma Surveillance Counterpoint: Australia

Andrew J. Spillane and Meagan E. Brennan

57. Breast Carcinoma Surveillance Counterpoint: Japan

Eriko Tokunaga and Yoshihiko Maehara

58. Endometrial Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

59. Endometrial Cancer Surveillance Counterpoint: USA

Amit Bhate, Eric Donnelly, John Lurain, Julian Schink, and William Small Jr.

60. Endometrial Cancer Surveillance Counterpoint: USA

Summer B. Dewdney and Premal H. Thaker